Nutex Health (NASDAQ:NUTX) Announces Earnings Results

Nutex Health (NASDAQ:NUTX) posted its quarterly earnings data on Thursday. The company reported $5.71 EPS for the quarter, topping analysts’ consensus estimates of $5.54 by $0.17, FiscalAI reports. The company had revenue of $217.61 million for the quarter, compared to analyst estimates of $214.82 million. Nutex Health had a return on equity of 39.74% and a net margin of 21.25%.

Nutex Health Trading Down 6.8%

Shares of NASDAQ NUTX traded down $13.08 during mid-day trading on Friday, hitting $180.56. The company’s stock had a trading volume of 167,920 shares, compared to its average volume of 138,903. Nutex Health has a one year low of $83.99 and a one year high of $226.16. The company’s fifty day simple moving average is $203.11 and its 200-day simple moving average is $151.38. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.00 and a quick ratio of 4.96. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of 7.71 and a beta of 0.66.

Insider Buying and Selling at Nutex Health

In related news, Director Scott Saunders sold 203 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $214.25, for a total transaction of $43,492.75. Following the completion of the sale, the director directly owned 400 shares of the company’s stock, valued at $85,700. The trade was a 33.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 44.68% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have commented on NUTX. Lake Street Capital reissued a “buy” rating and set a $310.00 price objective (up from $235.00) on shares of Nutex Health in a report on Tuesday, August 11th. LADENBURG THALM/SH SH assumed coverage on shares of Nutex Health in a research report on Monday, October 26th. They issued a “buy” rating and a $336.00 price objective for the company. Weiss Ratings upgraded shares of Nutex Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, October 6th. Zacks Research downgraded Nutex Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. Finally, B. Riley Financial reiterated a “buy” rating on shares of Nutex Health in a research report on Friday, September 4th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Nutex Health has a consensus rating of “Moderate Buy” and an average price target of $323.67.

Nutex Health Company Profile

Nutex Health, Inc (NASDAQ:NUTX) is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.